Lopressor (Metoprolol Tartrate) 25–100 mg Tablets / Toprol-XL (Metoprolol Succinate) 25–200 mg ER Tablets: Prescription Cardioselective Beta-1 Blocker for Hypertension, Angina, and Heart Failure — IR vs ER Formulations Explained

Information last reviewed: May 2026 — for educational purposes only.

Metoprolol is a beta-1 selective (cardioselective) adrenergic receptor blocker that exists in two distinct pharmacological forms: metoprolol tartrate (Lopressor) and metoprolol succinate (Toprol-XL). These are not interchangeable on a milligram-for-milligram basis and have different approved indications, dosing schedules, and clinical outcomes data. Understanding the distinction is clinically important.

Uses and the Critical Tartrate vs Succinate Distinction

Metoprolol tartrate (Lopressor) is an immediate-release formulation taken twice daily. It is used for hypertension, angina, and acute myocardial infarction (where IV formulation is also available for acute arrhythmias and MI). Metoprolol succinate (Toprol-XL) is an extended-release formulation taken once daily. It is FDA-approved not only for hypertension and angina but also specifically for chronic heart failure with reduced ejection fraction (HFrEF), where it has robust clinical trial evidence demonstrating significant mortality reduction — an indication that is not shared by the IR tartrate form. The succinate XL form should be used when treating heart failure.

Mechanism, Warnings, and Key Interactions

Metoprolol selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, contractility, and myocardial oxygen consumption. Its cardioselectivity means it has substantially less beta-2 blockade than non-selective agents like propranolol, which reduces — but does not eliminate — the risk of bronchospasm in patients with asthma or COPD. Caution is still warranted at higher doses. Metoprolol must never be stopped abruptly in patients with coronary artery disease or heart failure — sudden withdrawal can trigger rebound angina, myocardial infarction, or haemodynamic decompensation. The dose should be tapered gradually. Because it is beta-1 selective, it does not mask hypoglycaemia symptoms as completely as propranolol, but caution is still warranted in insulin-dependent diabetics. Bradycardia, fatigue, and sexual dysfunction are common side effects. Combining metoprolol with rate-limiting drugs such as amiodarone, verapamil, or diltiazem increases the risk of severe bradycardia and AV block.

Available Strengths and Dosing

Metoprolol tartrate (Lopressor) IR tablets are available in 25 mg, 50 mg, and 100 mg, typically dosed twice daily for hypertension. Metoprolol succinate (Toprol-XL) ER tablets come in 25 mg, 50 mg, 100 mg, and 200 mg for once-daily dosing. For heart failure, the succinate form is started at a low dose (typically 12.5–25 mg once daily) and titrated slowly upward over weeks as tolerated — the target dose from clinical trials is 200 mg once daily.

Pricing Overview

Both metoprolol tartrate and metoprolol succinate are available in affordable generic forms. Tartrate is among the cheapest beta-blockers available. Generic succinate ER is also inexpensive though historically more costly than tartrate. Branded Lopressor and Toprol-XL are more expensive. Contact Lucas Clinic for current pricing and product availability.

Frequently Asked Questions

Can metoprolol tartrate and metoprolol succinate be substituted for one another?

They should not be interchanged without careful consideration. Beyond the difference in dosing frequency (twice vs once daily), the two salts have different release profiles and pharmacokinetics. More critically, only the succinate ER form is FDA-approved for chronic heart failure. Switching a stable HF patient from Toprol-XL to the tartrate form is clinically inappropriate and may compromise outcomes. Always verify which formulation a patient is taking when reviewing or updating prescriptions.

Why is Toprol-XL specifically used in heart failure but Lopressor is not?

The MERIT-HF trial specifically demonstrated that metoprolol succinate (Toprol-XL) in stable, well-titrated HFrEF patients reduced all-cause mortality by approximately 34% compared to placebo. This evidence base was generated exclusively with the succinate ER formulation. The immediate-release tartrate form produces higher peak levels and greater fluctuation, which is not suitable for the carefully controlled up-titration regimen required in heart failure management. The FDA approval for HFrEF is salt-specific and applies only to Toprol-XL.

Is metoprolol safer than propranolol in patients with lung disease?

Yes, relatively. Metoprolol's beta-1 selectivity means much less beta-2 receptor blockade at standard therapeutic doses compared to propranolol, which is non-selective. Beta-2 blockade in the airways causes bronchoconstriction, which is dangerous in asthma and problematic in COPD. At low to moderate doses, metoprolol is generally considered cautiously acceptable in mild-to-moderate COPD, whereas propranolol is generally avoided in any obstructive lung disease. However, cardioselectivity diminishes at high doses, so metoprolol should still be used with care in patients with significant reversible obstructive disease.

← Back to Blood Pressure Medications